Takeda’s gene editing partner is snapped up for $250M cash as sector continues to heat up
Looking to make genome editing its “fourth pillar” of operations, Japan’s AnGes is buying out Takeda-partnered EmendoBio for $250 million — and with it, technology designed to push past the current limitations of CRISPR gene editing.
AnGes led EmendoBio’s $61 million Series B a little less than a year ago, contributing $50 million and upping its stake in the New York biotech to 32%. Now it’s snapping up the rest, making Emendo an independent but wholly-owned subsidiary.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.